Intensified Efforts Required to Withdraw Oral Artemisinin-based Monotherapies. (WHO Drug Information Vol. 28, No. 2, 2014)
(2014; 7 pages)


The emergence and spread of artemisinin resistance calls for intensified efforts to withdraw oral artemisinin-based monotherapy (oAMT) from the markets. Despite substantial progress, oAMTs are still available in many countries.

Intensified action is needed to protect the therapeutic life of artemisininbased combination therapy (ACT), the mainstay of treatment for malaria caused by Plasmodium falciparum. No alternative medicine is ready to enter the market in the next few years to replace ACTs. The loss of this lifesaving class of medicines would have devastating consequences.

El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019